Abstract Purpose Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …

Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …

Background The objective of this study was to evaluate if 18 F-fluorodeoxyglucose positron
emission tomography/computed tomography (18 F-FDG PET/CT)-derived parameters are …

Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in
patients with previously treated non-small cell lung cancer. However, little is known about …

Aim The aim of this study was to assess the predictive role of fluorine-18-fluorodeoxyglucose
(18 F-FDG) PET/computed tomography (CT) in the evaluation of response to immunotherapy …

Purpose Eliciting antitumor T-cell response by targeting the PD-1/PD-L1 axis with
checkpoint inhibitors has emerged as a novel therapeutic strategy in non-small cell lung …

The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell
death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To …

Abstract Anti-programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)
antibodies are administered in varied human cancer types. The expression of PD-L1 within …

Simple Summary Lung cancer is the leading cause of cancer-related death worldwide.
Nonsmall cell lung cancer (NSCLC) accounts for 80–85% of all cases. Immune checkpoint …

Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …